1. Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype
- Author
-
Vermunt, L., Sikkes, S. A. M., van den Hout, A., Handels, R., Bos, I., van der Flier, W. M., Kern, S., Ousset, P. -J., Maruff, P., Skoog, I., Verhey, F. R. J., Freund-Levi, Y., Tsolaki, M., Wallin, A. K., Olde Rikkert, M., Soininen, H., Spiru, L., Zetterberg, H., Blennow, K., Scheltens, P., Muniz-Terrera, G., Visser, P. J., Vellas, B., Reynish, E., Ousset, P. J., Andrieu, S., Burns, A., Pasquier, F., Frisoni, G., Salmon, E., Michel, J. P., Zekry, D. S., Boada, M., Dartigues, J. F., Olde-Rikkert, M. G. M., Rigaud, A. S., Winblad, B., Malick, A., Sinclair, A., Frolich, L., Ribera, C., Touchon, J., Robert, P., Salva, A., Waldemar, G., Bullock, R., Rodriguez, G., Jones, R. W., Stiens, G., Stoppe, G., Eriksdotter Jonhagen, M., Cherubini, A., Lage, P. M., Gomez-Isla, T., Camus, V., Aguera-Morales, E., Lopez, F., Savy, S., Cantet, C., Coley, N., Psychiatrie & Neuropsychologie, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, MUMC+: MA Med Staf Spec Psychiatrie (9), Neurology, Amsterdam Neuroscience - Neurodegeneration, NCA - neurodegeneration, APH - Personalized Medicine, APH - Methodology, Epidemiology and Data Science, Clinical Neuropsychology, and Zekry Berger, Dina Selma
- Subjects
0301 basic medicine ,Apolipoprotein E ,Oncology ,Male ,NATIONAL INSTITUTE ,MILD COGNITIVE IMPAIRMENT ,Neurology ,Alzheimer`s disease Donders Center for Medical Neuroscience [Radboudumc 1] ,Time Factors ,Epidemiology ,Apolipoprotein E4 ,Disease ,RECOMMENDATIONS ,0302 clinical medicine ,Cerebrospinal fluid ,Genotype ,Longitudinal Studies ,Apolipoprotein E4/genetics ,Stage (cooking) ,Progression ,Health Policy ,Cognitive Dysfunction/pathology ,NEURODEGENERATION ,Alzheimer's disease ,Preclinical ,3. Good health ,PREVALENCE ,Psychiatry and Mental health ,Disease Progression ,lipids (amino acids, peptides, and proteins) ,Female ,ASSOCIATION WORKGROUPS ,APOE ,medicine.medical_specialty ,Amyloid ,Multistate model ,BETA-AMYLOID 1-42 ,Prodromal Symptoms ,tau Proteins ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,Sex Factors ,Developmental Neuroscience ,SDG 3 - Good Health and Well-being ,Alzheimer Disease ,Internal medicine ,mental disorders ,medicine ,Dementia ,Humans ,Biomarkers/cerebrospinal fluid ,Cognitive Dysfunction ,Alleles ,Aged ,Disease duration ,DECLINE ,business.industry ,tau Proteins/cerebrospinal fluid ,Alzheimer Disease/genetics/pathology ,medicine.disease ,Institutional repository ,Clinical setting ,030104 developmental biology ,Prodromal ,Positron-Emission Tomography ,ddc:618.97 ,RISK-FACTORS ,DIAGNOSTIC GUIDELINES ,Neurology (clinical) ,Geriatrics and Gerontology ,business ,030217 neurology & neurosurgery ,Biomarkers - Abstract
Introduction: We estimated the age-specific duration of the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD) and the influence of sex, setting, apolipoprotein E (APOE) genotype, and cerebrospinal fluid tau on disease duration.Methods: We performed multistate modeling in a combined sample of 6 cohorts (n = 3268) with death as the end stage and estimated the preclinical, prodromal, and dementia stage duration.Results: The overall AD duration varied between 24 years (age 60) and 15 years (age 80). For individuals presenting with preclinical AD, age 70, the estimated preclinical AD duration was 10 years, prodromal AD 4 years, and dementia 6 years. Male sex, clinical setting, APOE epsilon 4 allele carriership, and abnormal cerebrospinal fluid tau were associated with a shorter duration, and these effects depended on disease stage.Discussion: Estimates of AD disease duration become more accurate if age, sex, setting, APOE, and cerebrospinal fluid tau are taken into account. This will be relevant for clinical practice and trial design. (C) 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
- Published
- 2019
- Full Text
- View/download PDF